The TriClip system for edge-to-edge transcatheter tricuspid valve repair. A Spanish multicenter study.

Cardiopatía valvular Heart failure Heart valve diseases Insuficiencia cardiaca Insuficiencia cardiaca derecha Insuficiencia tricuspídea Reparación transcatéter de la válvula tricúspide Right sided Transcatheter tricuspid valve repair Tricuspid regurgitation

Journal

Revista espanola de cardiologia (English ed.)
ISSN: 1885-5857
Titre abrégé: Rev Esp Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101587954

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 27 09 2021
accepted: 28 01 2022
pubmed: 16 3 2022
medline: 28 9 2022
entrez: 15 3 2022
Statut: ppublish

Résumé

In patients with tricuspid regurgitation (TR), edge-to-edge transcatheter tricuspid valve repair (TTVR) is the strategy with the highest penetration worldwide. A dedicated edge-to-edge TTVR system has recently become available in Europe. The present study describes the initial experience with the system in Spain. This multicenter study collected individual data from the centers accepted for the use of the novel system within an initial limited release. Between June 2020 and March 2021, all patients undergoing an edge-to-edge TTVR using the TriClip system in Spain were included in the study. The primary endpoint was the achievement of a TR reduction of at least 1 grade at discharge. We included 34 patients. Most of them reported a previous history of atrial fibrillation (91%) and only 1 had a pacemaker lead. The primary endpoint (TR reduction of at least 1 grade at discharge) was met in all patients. Most of the patients required 1 (47%) or 2 clips (44%) with a clear predominance of XT (87%) over NT (13%). The location of the first clip was anteroseptal in >90% of the patients. Only 1 patient had a partial detachment, which was stabilized with additional clips in the same procedure. At discharge, TR severity was≤2 in 91% of patients. At 3 months, mortality was nil. Overall, 88% of patients were in New York Heart Association functional class≤2 and 80% had residual TR≤2. Edge-to-edge TTVR seemed to be effective and safe with a sustained TR reduction at 3 months. Further studies will be needed to confirm our findings.

Identifiants

pubmed: 35288060
pii: S1885-5857(22)00028-7
doi: 10.1016/j.rec.2022.01.007
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

797-804

Informations de copyright

Copyright © 2022 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Xavier Freixa (X)

Departamento de Cardiología, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: Freixa@clinic.cat.

Dabit Arzamendi (D)

Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

María Del Trigo (M)

Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.

Pedro Luis Cepas-Guillén (PL)

Departamento de Cardiología, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Pedro Li (P)

Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Laura Sanchis (L)

Departamento de Cardiología, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Manuel Barreiro (M)

Servicio de Cardiología, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain.

Ander Regueiro (A)

Departamento de Cardiología, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

José Antonio Baz (JA)

Servicio de Cardiología, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain.

Lluis Asmarats (L)

Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Fran Calvo (F)

Servicio de Cardiología, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain.

Vanessa Moñivas (V)

Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.

Irene Meduiña (I)

Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Javier Goicolea (J)

Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.

Marta Sitges (M)

Departamento de Cardiología, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Rodrigo Estévez-Loureiro (R)

Servicio de Cardiología, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH